Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nanjing Pharmaceutical Group (600713) Fair Value & Analysis

Healthcare · CN · Market cap 6.6B CNY

Price¥5.00
Fair Value¥9.46
Upside+89.2%
Quality90/100
Evidence: High Range ¥4.80 – ¥12.30

Analysis

Nanjing Pharmaceutical Group (600713) currently trades at ¥5.00, while our model-based Fair Value estimate is ¥9.46 — implying the stock looks roughly 89.2% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nanjing Pharmaceutical Group Company Limited was founded in 1951 and is based in Nanjing, China.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -23% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% Merck & Co (MRK) +10% AstraZeneca PLC (A1ZN34) -31%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.